Business Wire

Results from Blue Earth Diagnostics’ FALCON Trial Show 64% of Patients with Suspected Recurrent Prostate Cancer Had Change in Management Following Axumin® (Fluciclovine F 18 ...

BURLINGTON, Mass. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company focused on molecular imaging diagnostics, today announced results from an investigational clinical trial ...
Business Wire

U.S. FDA Approves Blue Earth Diagnostics’ Axumin™ (Fluciclovine F 18) Injection after Priority Review for PET Imaging of Recurrent Prostate Cancer

In patients with PSA levels ≤ 1.78 ng/mL, 15 of 25 had a positive scan, with 11 confirmed as positive by histology; 71 of 74 patients with PSA levels > 1.78 ng/mL had a positive scan, of which 58 were ...
Victorville Daily Press

Scan offers improved cancer cell detection

VICTORVILLE — A new prostate cancer scan that is extending the lives of patients is now available in the High Desert. Axumin is a recently FDA-approved imaging agent that detects recurrent cancer ...
News Medical

Axumin approved for use in PET scans in patients with recurrent prostate cancer

The U.S. Food and Drug Administration today approved Axumin, a radioactive diagnostic agent for injection. Axumin is indicated for positron emission tomography (PET) imaging in men with suspected ...
Finanznachrichten

Blue Earth Diagnostics Announces Results of an Analysis of the Impact of Axumin (Fluciclovine F 18) PET/CT Imaging on Androgen Deprivation Therapy (ADT) Planning in Recurrent ...

This analysis characterized the impact of Axumin PET/CT on sites of disease recurrence and plans for androgen deprivation therapy (ADT) in patients with biochemical recurrence of prostate cancer. Of ...